About Orbital Therapeutics
Orbital Therapeutics is a company based in Yellow Springs (United States) founded in 2022 was acquired by Bristol-Myers Squibb in October 2025. Orbital Therapeutics has raised $270 million across 1 funding round from investors including ARE, Exor and Arch Venture Partners. Orbital Therapeutics offers products and services including RNA Medicines Platform and State-of-the-Art Technologies. Orbital Therapeutics operates in a competitive market with competitors including Cardinal Health, Harrow, FFF Enterprises, Threshold Enterprises and Senderra Rx, among others.
- Headquarter Yellow Springs, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$270 M (USD)
in 1 rounds
-
Latest Funding Round
$270 M (USD), Series A
Apr 26, 2023
-
Investors
ARE
& 13 more
-
Employee Count
Not available
-
Acquired by
Bristol-Myers Squibb
(Oct 10, 2025)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Orbital Therapeutics
Orbital Therapeutics offers a comprehensive portfolio of products and services, including RNA Medicines Platform and State-of-the-Art Technologies.
Platform for designing RNA medicines tailored to specific diseases
Tools for calibrating RNA expression and tissue distribution in medicines
People of Orbital Therapeutics
Unlock access to complete
Funding Insights of Orbital Therapeutics
Orbital Therapeutics has successfully raised a total of $270M through 1 strategic funding round. The most recent funding activity was a Series A round of $270 million completed in April 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Orbital Therapeutics
Orbital Therapeutics has secured backing from 14 investors, including venture fund and institutional investors. Prominent investors backing the company include ARE, Exor and Arch Venture Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm focused on life science companies
|
Locked | Locked | Locked | |
|
Venture capital investments in technology sectors are handled by Andreessen Horowitz.
|
Locked | Locked | Locked | |
|
Investment management services are offered by Newpath Partners.
|
Locked | Locked | Locked |
Investor details for Orbital Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Orbital Therapeutics
Investment portfolio details for Orbital Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Orbital Therapeutics
Detailed financials for Orbital Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Orbital Therapeutics Comparisons
Peer comparison for Orbital Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Orbital Therapeutics
Orbital Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Cardinal Health, Harrow, FFF Enterprises, Threshold Enterprises and Senderra Rx, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Multiple healthcare products and services are provided to organizations.
|
|
| Locked | Locked | Locked |
Ophthalmic products marketing services are provided by Harrow.
|
|
| Locked | Locked | Locked |
Distributes critical-care pharmaceuticals, vaccines, and specialty products to healthcare providers.
|
|
| Locked | Locked | Locked |
Distributors of fine natural and specialty products
|
|
| Locked | Locked | Locked |
Offers specialty medications, delivery, and support for patients with diseases like asthma and cancer.
|
Detailed competitors of Orbital Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Orbital Therapeutics
Complete news archive for Orbital Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Orbital Therapeutics
Orbital Therapeutics was founded in 2022 and raised its 1st funding round 1 year after it was founded.
Orbital Therapeutics is headquartered in Yellow Springs, United States. It is registered at Yellow Springs, Ohio, United States.
Ron Philip is the current CEO of Orbital Therapeutics.
Orbital Therapeutics is a funded company, having raised a total of $270M across 1 funding round to date.
Orbital Therapeutics, backed by 270000000.0 from Arch Venture Partners, Andreessen Horowitz, Newpath Partners, ADG, Redmile Group, Exor, Invus, Moore Ventures, IGlobe Partners, Casdin Capital, Agent Capital, Alexandria, Heritage Medical Systems, focuses on providing healthcare solutions, pharmaceutical distributors, and specialty drugs. Distributor of RNA medicines. Driving innovation, growth, and excellence in its industry sectors.
Orbital Therapeutics's top competitors include Cardinal Health, Harrow and Threshold Enterprises.
Orbital Therapeutics offers RNA Medicines Platform and State-of-the-Art Technologies.
Orbital Therapeutics has 14 investors. Key investors include ARE, Exor, Arch Venture Partners, Bristol-Myers Squibb, and Andreessen Horowitz.